Prism Medico and Pharmacy Ltd (PRISMMEDI) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Prism Medico and Pharmacy Ltd on NSE and BSE, with an AI summary of each filing.
Prism Medico And Pharmacy Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve - Consider, approve ....
Intimation · 05 Nov 2026, 5:30 am
Prism Medico and Pharmacy Schedules Board Meeting for Q2 FY27 Financial Results Prism Medico and Pharmacy Limited has scheduled a meeting of its Board of Directors on 5th Nov'26 at its registered office in Himachal Pradesh. The board will primarily consider, approve, and take on record the company's Unaudited Standalone Financial Results along with the Limited Review Report for the quarter ended 30th Sep'26, pursuant to Regulation 33 of SEBI LODR Regulations, 2015, alongside other routine corporate business matters.
Dear Sir/ Madam, Pursuant to Regulation 46 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find attached the intimation ....
Others (Uncategorized) · 29 Oct 2026, 7:48 pm
Prism Medico Confirms Functional Website Compliance Under SEBI LODR Regulations Prism Medico and Pharmacy Limited has submitted a regulatory undertaking confirming that its official website (https://www.prismmedico.in) is fully updated and functional in compliance with Regulation 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as of 29th Oct'26.
Dear Sir/ Madam Pursuant to Regulation 57(5) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR), please find the ....
Others (Uncategorized) · 05 Oct 2026, 9:52 pm
Prism Medico and Pharmacy Reports Nil Debt Payment Obligations Prism Medico and Pharmacy Limited submitted a compliance intimation under Regulation 57(5) of SEBI LODR Regulations for the quarter ended 30th Sep'26. The company confirmed that it has not issued any non-convertible securities. Consequently, there were no interest, dividend, or principal payment obligations due during the quarter spanning 1st Jul'26 to 30th Sep'26.
Dear Sir/ Madam, Pursuant to Regulation 57(4) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements), Regulations, 2015 (LODR), please find the ....
Others (Uncategorized) · 30 Sept 2026, 9:04 pm
Prism Medico and Pharmacy Reports Nil Debt Obligations for Q3 FY27 Prism Medico and Pharmacy Limited has submitted a regulatory disclosure under SEBI LODR Regulation 57(4) confirming that it has no non-convertible securities with interest, dividend, or principal obligations payable during the quarter spanning 1st Oct'26 to 31st Dec'26. Consequently, the company has zero scheduled debt service or redemption cash outflows related to non-convertible securities for the period.
Dear Sir/ Madam, Pursuant to Provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and provisions of Regulation ....
Annual General Meeting · 23 Sept 2026, 12:28 am
Dear Sir/Madam, Pursuant to Regulation 30(2) of SEBI (LODR) Regulations, 2015 please find the attached proceedings of the 24th Annual General Meeting of the members of the company held ....
Audio / Video · 19 Sept 2026, 7:18 pm
Dear Sir/Madam, The stock exchanges are informed that the 24th Annual General Meeting of the members of the company was held on Saturday the 19th day of September, 2026 at 12:30 P.M. ....
Annual General Meeting · 19 Sept 2026, 6:49 pm
Dear Sir/Madam, Pursuant to Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith ....
Others (Uncategorized) · 26 Aug 2026, 9:25 pm
Dear Sir/ Madam, Please find attached herewith intimation of Record Date for the purpose of conducting the 24th Annual General Meeting of the company to be held for the financial year ....
Others · 24 Aug 2026, 11:41 pm
Dear Sir/ Madam, Pursuant to Regulation 34 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith ....
Annual Report · 24 Aug 2026, 11:10 pm
Dear Sir/ Madam, Pursuant to Regulation 34 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith ....
Annual Report · 24 Aug 2026, 11:09 pm
Dear Sir/Madam, The 24th Annual General Meeting of M/s. Prism Medico and Pharmacy is scheduled to be held on 19th September, 2026 through VC/OAVM. The notice of the same is attached ....
Annual General Meeting · 24 Aug 2026, 10:39 pm
1. Considered & approved: (i) Director''s Report for the F.Y. ended March 31, 2026 (ii) notice of 24th AGM to be held on September 19, 2026 at 12:30 P.M. through VC/OAVM 2. Fixed date ....
Outcome · 24 Aug 2026, 10:10 pm
Prism Medico And Pharmacy Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/08/2026 ,inter alia, to consider and approve ? To consider and ....
Intimation · 19 Aug 2026, 10:38 pm
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors at their meeting held ....
Outcome · 12 Aug 2026, 9:19 pm
Prism Medico Q1FY27 Results: Net Loss Declines on Lower Revenue Prism Medico reported a reduced net loss of ₹0.24 Cr for Q1FY27 ending 30 Jun'26, compared to a loss of ₹0.28 Cr YoY, despite a 49% YoY decline in revenue from operations to ₹0.28 Cr. The improvement was driven by a significant 65% YoY drop in total expenses to ₹0.41 Cr, primarily due to lower material costs. The Board of Directors approved these unaudited standalone financial results on 12 Aug'26. Diluted EPS for the quarter was ₹(0.0040), compared to ₹(0.0046) YoY.
Dear Sir/Madam, This is to inform you that the website of M/s. Prism Medico and Pharmacy Limited is updated and functional as per Regulation 46 of Securities and Exchange Board of India ....
Others (Uncategorized) · 31 Jul 2026, 12:03 am
Prism Medico Confirms Functional Website as per SEBI Regulations Prism Medico and Pharmacy Limited (BSE: 512217, MSEI: PRISMMEDI) submitted an undertaking on 30 Jul'26, confirming its website (www.prismmedico.in) is updated and functional. This complies with Regulation 46 of the SEBI (LODR) Regulations, 2015. The notification ensures the company meets regulatory requirements for timely investor information disclosure, a key governance checkpoint. No other financial or operational updates were provided in the filing.
Dear Sir/Madam, Please find the attache statements of investor complaints for the quarter ended 30th June, 2026. You are requested to kindly take the same on record and oblige. Thanking ....
Others (Uncategorized) · 21 Jul 2026, 8:05 pm
Prism Medico Reports Zero Investor Complaints for Q1FY27 Prism Medico and Pharmacy Limited reported zero investor complaints for the quarter ended 30th Jun'26, as per its regulatory filing. The company confirmed there were no complaints pending at the start of the quarter, none were received or disposed of during the period, and none remained unresolved at the quarter's end. This filing complies with SEBI's Regulation 13(3) for listing obligations and disclosure requirements.
Dear Sir/Madam, Pursuant to Regulation 57(5) of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, please find the attached intimation for your reference and ....
Others (Uncategorized) · 06 Jul 2026, 10:57 pm
Prism Medico Confirms No Debt Obligations for Q1 FY27 Prism Medico and Pharmacy Limited (PRISMMEDI) confirmed on 06 Jul'26, pursuant to SEBI's LODR Regulation 57(5), that it had no outstanding non-convertible securities. Consequently, the company had no interest, dividend, or principal payment obligations due for the quarter ended 30 Jun'26. This indicates no near-term cash outflow related to debt servicing for the specified period, signaling a clean debt slate regarding listed non-convertible instruments.
Pursuant to Regulation 57(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR), please find the attached intimation ....
Others (Uncategorized) · 30 Jun 2026, 9:47 pm
Prism Medico Confirms No NCD Payments Due in Q2 FY27 Prism Medico and Pharmacy Limited has notified exchanges under SEBI LODR Regulation 57(4) that it has not issued any non-convertible securities. Consequently, no interest, dividend, or principal payments are due for the quarter beginning 01 Jul'26 and ending 30 Sep'26. This confirms no debt servicing obligations related to such instruments for the specified period.
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors at their meeting held ....
Outcome · 28 May 2026, 10:39 pm
Prism Medico Reports Q4 & FY26 Results with Unmodified Audit Opinion Prism Medico and Pharmacy's board approved audited standalone results for the quarter and year ended 31st Mar'26. For FY26, the company reported a Net Profit of ₹31.84 Lakhs on revenue of ₹244.34 Lakhs, a significant turnaround from an FY25 loss of ₹4.87 Lakhs. Q4 FY26 saw revenue of ₹28.14 Lakhs with a Net Loss of ₹24.07 Lakhs. The statutory auditors, Garg Mendiratta & Associates, issued an unmodified "true and fair" opinion on the financial statements for the year.
Prism Medico And Pharmacy Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve With reference to ....
Intimation · 28 May 2026, 5:30 am
Prism Medico Sets Board Meeting for Q4 & FY26 Results Approval Prism Medico and Pharmacy Ltd has scheduled a Board of Directors meeting on 28 May'26. The agenda includes the consideration and approval of the Audited Standalone Financial Results for the fourth quarter and financial year ended 31 Mar'26. The board will also take on record the accompanying Auditors Report.
Dear Sir / Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors ....
Others (Uncategorized) · 11 May 2026, 10:23 pm
Prism Medico Appoints S Harpreet and Associates as Internal Auditors for FY26 Prism Medico and Pharmacy's Board of Directors approved the appointment of Mr. Harpreet Singh of M/s. S Harpreet and Associates, Chartered Accountants, as the company's internal auditors for the financial year 2025-2026. The decision was made at the board meeting held on 11th May'26. This appointment is a key corporate governance update for the upcoming fiscal year.
With reference to the subject cited, this is to inform the Exchange that the meeting of the Board of Directors of Prism Medico and Pharmacy Limited held on Tuesday, May 05, 2026 at the ....
Others (Uncategorized) · 05 May 2026, 10:04 pm
Prism Medico Approves Preferential Allotment of Equity Shares and Warrants Prism Medico and Pharmacy's board, on May 05, '26, approved a preferential allotment of 75 lakh equity shares and 50 lakh convertible warrants. Both instruments have a face value and issue price of ₹10 each. This action follows the special resolution passed at the EGM on Mar 20, '26, and the in-principle approval from the BSE received on Mar 25, '26. The move will lead to equity dilution upon allotment and subsequent warrant conversion, potentially raising ₹12.5 crore in total capital for the company.
With reference to the subject cited, this is to inform the Exchange that the meeting of the Board of Directors of Prism Medico and Pharmacy Limited held on Tuesday, May 05, 2026 at the ....
Others (Uncategorized) · 05 May 2026, 9:59 pm
Prism Medico Board Approves Preferential Allotment of Equity and Warrants Prism Medico and Pharmacy's board, in a meeting on 05 May'26, approved a preferential allotment of 75 lakh equity shares and 50 lakh convertible warrants. Both instruments have a face value of ₹10 and an issue price of ₹10. This action follows the special resolution passed at the EGM on 20 Mar'26 and in-principle approval from the BSE on 25 Mar'26. The allotment will lead to equity dilution and capital infusion for the company.
Dear Sir/Madam, Please find the attached confirmation regarding non-applicability of large corporate entity framework. You are requested to take the same on record and oblige. Thanks ....
Others (Uncategorized) · 29 Apr 2026, 9:55 pm
Prism Medico Confirms Exemption from Large Corporate Entity Framework Prism Medico and Pharmacy Ltd. informed exchanges on 29 Apr'26 that it does not qualify as a "large corporate entity" as of 31 Mar'26, according to SEBI's framework. Consequently, the company is not required to comply with the associated disclosure and fund-raising norms mandated for such entities. This exemption relieves the company from the obligation to raise a portion of its incremental borrowings through debt securities.